CA3175350A1 - Methodes de prevention et de traitement de l'infection par la covid-19 - Google Patents

Methodes de prevention et de traitement de l'infection par la covid-19

Info

Publication number
CA3175350A1
CA3175350A1 CA3175350A CA3175350A CA3175350A1 CA 3175350 A1 CA3175350 A1 CA 3175350A1 CA 3175350 A CA3175350 A CA 3175350A CA 3175350 A CA3175350 A CA 3175350A CA 3175350 A1 CA3175350 A1 CA 3175350A1
Authority
CA
Canada
Prior art keywords
vitamin
administering
zinc
day
hydroxychloroquine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3175350A
Other languages
English (en)
Inventor
Sabine HAZAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/026,051 external-priority patent/US11253534B2/en
Priority claimed from US16/953,674 external-priority patent/US20210290718A1/en
Priority claimed from US17/114,271 external-priority patent/US11278520B2/en
Application filed by Individual filed Critical Individual
Publication of CA3175350A1 publication Critical patent/CA3175350A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Méthode de prévention d'une infection par la COVID-19 comprenant les étapes consistant : à administrer de l'hydroxychloroquine ; de la vitamine C ; de la vitamine D ; et du zinc ; et à surveiller l'état des individus sur une durée prédéterminée afin de déterminer que l'individu n'est pas infecté par la COVID-19. Méthode de traitement d'un individu infecté par la COVID-19 comprenant les étapes consistant : à administrer de l'hydroxychloroquine ; de l'azithromycine ; de la vitamine C ; de la vitamine D ; et du zinc ; et à surveiller l'état de l'individu sur une période de temps prédéterminée afin de déterminer si l'individu n'est plus infecté par la COVID-19. Les méthodes peuvent en outre comprendre l'administration d'ivermectine et facultativement de doxycycline.
CA3175350A 2020-03-23 2021-03-22 Methodes de prevention et de traitement de l'infection par la covid-19 Pending CA3175350A1 (fr)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US202062993370P 2020-03-23 2020-03-23
US202062993159P 2020-03-23 2020-03-23
US202062993345P 2020-03-23 2020-03-23
US62/993,370 2020-03-23
US62/993,159 2020-03-23
US62/993,345 2020-03-23
US202063001161P 2020-03-27 2020-03-27
US63/001,161 2020-03-27
US202063002494P 2020-03-31 2020-03-31
US63/002,494 2020-03-31
US202063022371P 2020-05-08 2020-05-08
US202063022368P 2020-05-08 2020-05-08
US63/022,371 2020-05-08
US63/022,368 2020-05-08
US17/026,051 US11253534B2 (en) 2020-03-23 2020-09-18 Method of preventing COVID-19 infection
US17/026,051 2020-09-18
US202063110877P 2020-11-06 2020-11-06
US63/110,877 2020-11-06
US16/953,674 US20210290718A1 (en) 2020-03-23 2020-11-20 Methods of preventing and treating covid-19 infection
US16/953,674 2020-11-20
US17/114,271 2020-12-07
US17/114,271 US11278520B2 (en) 2020-03-31 2020-12-07 Method of preventing COVID-19 infection
PCT/US2021/023486 WO2021194970A1 (fr) 2020-03-23 2021-03-22 Méthodes de prévention et de traitement de l'infection par la covid-19

Publications (1)

Publication Number Publication Date
CA3175350A1 true CA3175350A1 (fr) 2021-09-30

Family

ID=77892733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3175350A Pending CA3175350A1 (fr) 2020-03-23 2021-03-22 Methodes de prevention et de traitement de l'infection par la covid-19

Country Status (3)

Country Link
AU (1) AU2021241498A1 (fr)
CA (1) CA3175350A1 (fr)
WO (1) WO2021194970A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111658648A (zh) * 2020-02-03 2020-09-15 中国人民解放军军事科学院军事医学研究院 4-氨基喹啉类化合物在治疗冠状病毒感染方面的应用
WO2022126207A1 (fr) * 2020-12-20 2022-06-23 Topelia Aust Limited (Acn 652 771 670) Médicaments, combinaisons thérapeutiques et méthodes pour prévenir des infections virales et microbiennes et leurs séquelles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332475B2 (en) * 2003-07-22 2008-02-19 Kyowa Hakko Kogyo Co., Ltd. Preventive or therapeutic composition for viral infectious disease
WO2019199918A1 (fr) * 2018-04-11 2019-10-17 Cowan Fred M Compositions et méthodes pour la prévention et le traitement d'une maladie immune complexe
CR20210166A (es) * 2018-09-06 2021-07-27 Cidara Therapeutics Inc Composiciones y métodos para el tratamiento de infecciones virales
TW202104210A (zh) * 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
US10987329B1 (en) * 2020-04-22 2021-04-27 Nadimpally Satyavarahala Raju Combination therapy for coronavirus infections including the novel corona virus (COVID-19)

Also Published As

Publication number Publication date
WO2021194970A1 (fr) 2021-09-30
AU2021241498A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
Banerji et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach
Azarpazhooh et al. Xylitol for preventing acute otitis media in children up to 12 years of age
Hall et al. Recovery after open versus laparoscopic pyloromyotomy for pyloric stenosis: a double-blind multicentre randomised controlled trial
US11872242B2 (en) Methods of preventing and treating COVID-19 infection
Conterno et al. Anthelmintic drugs for treating ascariasis
Wong et al. A Lactobacillus casei Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial
US20210290718A1 (en) Methods of preventing and treating covid-19 infection
Hanna et al. Understanding COVID-19 pandemic: molecular mechanisms and potential therapeutic strategies. An evidence-based review
CA3175350A1 (fr) Methodes de prevention et de traitement de l'infection par la covid-19
McNeil et al. Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011–July 2018
US20220249547A1 (en) Method of preventing covid-19 infection
Behera et al. Prophylactic role of ivermectin in severe acute respiratory syndrome coronavirus 2 infection among healthcare workers
TW202206081A (zh) ９—胺甲基米諾四環素化合物及其用途
Morgenstern et al. Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in healthcare workers: a propensity score-matched retrospective cohort study
Verma et al. Assessing knowledge, attitude, and practices towards ivermectin pre-exposure prophylaxis for COVID-19 among health care workers
Llor et al. Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial
Chinawa et al. Mothers’ perception and management of abdominal colic in infants in Enugu, Nigeria
Jadav et al. Drug Utilization Study in Pediatric Patients with Typhoid Fever
Janas-Naze et al. Comparative Efficacy of Different Oral Doses of Clindamycin in Preventing Post-Operative Sequelae of Lower Third Molar Surgery—A Randomized, Triple-Blind Study
US20220226305A1 (en) Method and combination for treating viral infection and long hauler syndrome
Reece Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine
Dewangan et al. Incidence of Moxifloxacin serious adverse drug reactions in Pneumococcal infections virus infected patients detected by a Pharmacovigilance program by laboratory signals in a Tertiary hospital in Chhattisgarh (India)
KAWEN Scabies complete clearance as a treatment efficacy: in Permethrin alone and in combined with oral Ivermectin: South Iraq-2019.
Jokwiro Buddy Nurse
Kengar et al. Swine Flu and its Recent Medicines